Article info

Download PDFPDF
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Authors

  1. Correspondence to Dr Hafsah Nabi, DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark; hafsah.nabi{at}regionh.dk
View Full Text

Citation

Nabi H, Georgiadis S, Loft AG, et al
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Publication history

  • Received January 19, 2021
  • Revised April 9, 2021
  • Accepted April 10, 2021
  • First published April 29, 2021.
Online issue publication 
October 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.